Women are set to gain two new, taxpayer-funded, non-invasive tests for endometriosis, following a draft NICE recommendation for their regular use [1]. The two tests are Endosure from Maryland-based medtech EndoSure Inc, and Endotest, from French biotech Ziwig.
While the tests have been available through private payments, drug value watchdog NICE has now said that they can be made available via primary care doctors and paid for under the NHS.
The aim of the recommendation is to accelerate treatment of a disease that affects approximately 10 per cent of women of reproductive age in the UK and that many struggle to have formally diagnosed.
The average time to receive a diagnosis is more than nine years and the only current method to confirm endometriosis on the NHS is through a diagnostic laparoscopy, which NICE says is “invasive, costly, and carries surgical risks.”
The two tests set to be available on the NHS, pending final approval, are designed to be safer, more accessible and quicker options.
Ziwig’s Endotest analyses saliva samples for microRNAs, small biological markers that can show the presence of endometriosis. EndoSure, meanwhile, uses sensor pads on the abdomen that measure electrical signals in the gut to detect endometriosis. EndoTest requires patients to fast and drink water during the 45-minute test.
Anastasia Chalkidou, Ph.D., Healthtech Programme Director at NICE, said in a statement: “A diagnosis of endometriosis can for some women take the best part of a decade, with the UK average standing at nine years and four months, and rising to 11 years for those from ethnically diverse communities.”
“That delay means living with chronic pelvic pain that affects daily life, relationships and work. These technologies have the potential to change that by giving primary care professionals better non-invasive tools to identify endometriosis earlier allowing earlier and better treatment.”
In a statement, the NICE provided a proviso that the tests are to be used during a three-year period while additional evidence is collected on their efficiency.
A third technology, DotLab’s DotEndo blood test, has not been recommended by NICE, which says more research is required before it can recommend the NHS fund early use of it.
[1]: New technologies could help cut years-long wait for endometriosis diagnosis